IL10 and chronic kidney disease: Our study showed that local subcapsular delivery of Pr-MSCs reduces collagen deposition as well as increases the anti-inflammatory cytokine IL-10 in UUO-induced CKD, whereas no significant effect was observed after systemic administration.